Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well CCI-779 works in treating patients with progressive
metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as CCI-779, work in
different ways to stop tumor cells from dividing so they stop growing or die.